Inflarx NV (NASDAQ:IFRX) Receives $6.20 Consensus Target Price from Analysts
Shares of Inflarx NV (NASDAQ:IFRX) have been assigned an average recommendation of “Hold” from the eleven brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $6.20.
Separately, Zacks Investment Research lowered shares of Inflarx from a “buy” rating to a “hold” rating in a research note on Wednesday, October 23rd.
IFRX traded down $0.10 during trading on Thursday, hitting $3.46. 9,098 shares of the company traded hands, compared to its average volume of 1,175,168. Inflarx has a one year low of $2.17 and a one year high of $53.10. The stock’s fifty day moving average is $2.63 and its 200 day moving average is $6.48. The firm has a market cap of $88.28 million, a P/E ratio of -2.43 and a beta of -1.27.
Inflarx Company Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Read More: What is the Dividend Aristocrat Index?
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.